COLLINS, Miss. (WDAM) - As the Pine Belt gears up for another cold snap, Michael Mapp is looking ahead to ‘mudbug’ season. “It’ll be on into the end of February or first of March before we start ...

A suspect was in custody Saturday after an apparent arson attack set a Mississippi synagogue ablaze, destroying Torahs and prompting an investigation involving the FBI and the Joint Terrorism Task ...

What if you could combine the simplicity of Arduino with the power of a Linux-based processor, all in one compact device? Enter the Arduino Uno Q, a new development board designed to handle everything ...

SOUTHAVEN, Miss. — Elon Musk’s xAI will invest $20 billion in a Southaven facility, Mississippi Gov. Tate Reeves announced Thursday. It is the “largest single investment in Mississippi history,” ...

Mississippi State football looks to prove it belongs in bowl season when it faces Wake Forest in the Duke's Mayo Bowl on Jan. 2, the final day of regular bowl matchups. The Bulldogs failed to reach ...

The plan to fix five deteriorating bridges on U.S. 90 at the Mississippi-Louisiana state line is stalled again because a federal program that could fund the project has not reopened since the ...

Sanofi ( (SNY)) has shared an announcement. Sanofi announced on December 15, 2025, that the U.S. regulatory review process for tolebrutinib, a treatment for non-relapsing secondary progressive ...

Sanofi’s experimental multiple sclerosis drug got hit with two setbacks on Monday: a regulatory delay in the US as well as a failure in a late-stage clinical trial. The US Food and Drug Administration ...

Sanofi’s experimental multiple sclerosis drug tolebrutinib has encountered two major setbacks: a delayed regulatory decision in the U.S. and a failed late-stage clinical trial. The French drugmaker ...

That's exactly the way we're taught NOT to implement delay, and it doesn't handle the wrap of millis () corrected (ie when start+ms is larger than 32bits, and thus stop will be truncated and millis () ...

The clock is up on Biogen’s extra two years of a biosimilar-free U.S. market for its blockbuster multiple sclerosis (MS) med Tysabri. After waiting in the wings post-FDA approval in 2023, Sandoz’s ...